Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7768517 | 0.81 | — | — | |
| SCHEMBL9215170 | 0.77 | — | — | |
| SCHEMBL22209462 | 0.77 | NPSR1 (0.39) | NPSR1CYP4F2CYP4A11LMNAMAPT | |
| SCHEMBL10589247 | 0.77 | KDM4E (0.31) | CYP3A4KMT2A | |
| SCHEMBL10589244 | 0.77 | KDM4E (0.31) | CYP3A4KMT2A | |
| SCHEMBL2497821 | 0.75 | — | — | |
| SCHEMBL376992 | 0.75 | — | — | |
| SCHEMBL2183127 | 0.75 | — | — | |
| SCHEMBL19308 | 0.75 | — | — | |
| SCHEMBL313044 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12390446-B2 | Proline-based neuropeptide FF receptor modulators | RESEARCH TRIANGLE INSTITUTE (US) | 2025-08-19 | — | — | US | disclosed |
| US-20240058303-A1 | PROLINE-BASED NEUROPEPTIDE FF RECEPTOR MODULATORS | RES TRIANGLE INST (US) | 2024-02-22 | — | — | US | disclosed |
| US-11826350-B2 | Proline-based neuropeptide FF receptor modulators | RESEARCH TRIANGLE INSTITUTE (US) | 2023-11-28 | — | — | US | disclosed |
| CN-110546136-B | Proline-based neuropeptide FF receptor modulators | 研究三角协会 | 2023-07-18 | — | — | CN | disclosed |
| CN-116143678-A | Conjugate linker, cell-binding molecule-drug conjugate containing the same, and preparation and application thereof | 杭州多禧生物科技有限公司 | 2023-05-23 | — | — | CN | disclosed |
| US-20230091922-A1 | PROLINE-BASED NEUROPEPTIDE FF RECEPTOR MODULATORS | RES TRIANGLE INST (US) | 2023-03-23 | — | — | US | disclosed |
| US-11491136-B2 | Proline-based neuropeptide FF receptor modulators | RESEARCH TRIANGLE INSTITUTE (US) | 2022-11-08 | — | — | US | disclosed |
| CN-115300640-A | Novel linkers and their use for specific coupling of drugs and biomolecules | 杭州多禧生物科技有限公司 | 2022-11-08 | — | — | CN | disclosed |
| CN-108289964-B | Novel linkers and their use for specific coupling of drugs and biomolecules | 杭州多禧生物科技有限公司 | 2022-08-12 | — | — | CN | disclosed |
| US-20200030287-A1 | PROLINE-BASED NEUROPEPTIDE FF RECEPTOR MODULATORS | RESEARCH TRIANGLE INSTITUTE | 2020-01-30 | — | — | US | disclosed |
| CN-110546136-A | proline-based neuropeptide FF receptor modulators | RES TRIANGLE INST | 2019-12-06 | — | — | CN | disclosed |
| WO-2018152134-A1 | PROLINE-BASED NEUROPEPTIDE FF RECEPTOR MODULATORS | RESEARCH TRIANGLE INSTITUTE (US) | 2018-08-23 | — | — | WO | disclosed |
| US-20080176923-A1 | Proline Derivatives Used as Pharmaceutical Active Ingredients for the Treatment of Tumors | SALAMA ZOSER B | 2008-07-24 | — | — | US | disclosed |
| EP-0912172-B1 | COMBINATION OF CIS-4-HYDROXY-L-PROLINE AND N-METHYL-CIS-4-HYDROXY-L-PROLINE FOR USE AS A THERAPEUTIC AGENT, IN PARTICULAR IN CANCER TREATMENT | HOERRMANN WILHELM (DE) | 2000-09-06 | — | — | EP | disclosed |
| US-6066665-A | Combination of cis-4-hydroxy-L-proline and N-methyl-cis-4-hydroxy-L-proline for use as a therapeutic agent, in particular in cancer treatment | HOERRMANN WILHELM (DE) | 2000-05-23 | — | — | US | disclosed |
| EP-0912172-A1 | COMBINATION OF CIS-4-HYDROXY-L-PROLINE AND N-METHYL-CIS-4-HYDROXY-L-PROLINE FOR USE AS A THERAPEUTIC AGENT, IN PARTICULAR IN CANCER TREATMENT | Hoerrmann, Wilhelm, Dr. (DE) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997033578-A1 | COMBINATION OF CIS-4-HYDROXY-L-PROLINE AND N-METHYL-CIS-4-HYDROXY-L-PROLINE FOR USE AS A THERAPEUTIC AGENT, IN PARTICULAR IN CANCER TREATMENT | HOERRMANN WILHELM (DE) | 1997-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11491136-B2 | Proline-based neuropeptide FF receptor modulators | NPFFR1, NPFFR2, NPBWR1 | NPSR1 4/4885CYP4F2 722/4885CYP4A11 2647/4885 |
| US-12390446-B2 | Proline-based neuropeptide FF receptor modulators | NPFFR1, NPFFR2, NPBWR1 | NPSR1 4/4885CYP4F2 722/4885CYP4A11 2647/4885 |
| US-20200030287-A1 | PROLINE-BASED NEUROPEPTIDE FF RECEPTOR MODULATORS | NPFFR1, NPFFR2, NPBWR1 | NPSR1 4/4885CYP4F2 722/4885CYP4A11 2647/4885 |
| US-11826350-B2 | Proline-based neuropeptide FF receptor modulators | NPFFR1, NPFFR2, NPBWR1 | NPSR1 4/4885CYP4F2 722/4885CYP4A11 2647/4885 |
| US-20240058303-A1 | PROLINE-BASED NEUROPEPTIDE FF RECEPTOR MODULATORS | NPFFR1, NPFFR2, NPBWR1 | NPSR1 4/4885CYP4F2 722/4885CYP4A11 2647/4885 |
| US-20080176923-A1 | Proline Derivatives Used as Pharmaceutical Active Ingredients for the Treatment of Tumors | PREP, PRAP1, VHL | NPSR1 772/4885CYP4F2 4229/4885CYP4A11 3427/4885 |
| US-20230091922-A1 | PROLINE-BASED NEUROPEPTIDE FF RECEPTOR MODULATORS | NPFFR1, NPFFR2, NPBWR1 | NPSR1 4/4885CYP4F2 722/4885CYP4A11 2647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.